| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916033 | Nuclear Medicine and Biology | 2014 | 6 Pages |
Abstract
Alpha-RIT seems to be a good alternative to Melphalan. Association of these two treatments provides no benefit. The perspectives of this work would be to evaluate RIT impact on the regimens incorporating the novel agents bortezomide, thalidomide and lenalidomide.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S. Gouard, A. Pallardy, J. Gaschet, A. Faivre-Chauvet, F. Bruchertseifer, A. Morgenstern, C. Maurel, E. Matous, F. Kraeber-Bodéré, F. Davodeau, M. Chérel,